Gilead Sciences Beats Q4 EPS Forecast

Gilead Sciences (NASDAQ:GILD), a major player in the biotechnology sector, reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 11, that topped analysts' consensus estimates. Adjusted earnings per share of $1.90 came in well ahead of the estimated $1.74. Revenue for the quarter hit $7.57 billion compared to the expected $7.15 billion. A key highlight was the robust performance in the HIV and oncology segments, contributing to an optimistic assessment of the quarter. However, challenges such as declining Veklury sales and increased research and development expenses were noted.Source: Gilead Sciences. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year. bps = Basis points.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool